製品名:3-Fluoro-2-nitropyridine

IUPAC Name:3-fluoro-2-nitropyridine

CAS番号:54231-35-5
分子式:C5H3FN2O2
純度:98%
カタログ番号:CM103502
分子量:142.09

包装単位 有効在庫 価格(USD) 数量
CM103502-100g in stock ƤDzDz
CM103502-500g in stock ƋǕDzDz
CM103502-1000g in stock ȌɐȦſ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:54231-35-5
分子式:C5H3FN2O2
融点:-
SMILESコード:O=[N+](C1=NC=CC=C1F)[O-]
密度:
カタログ番号:CM103502
分子量:142.09
沸点:255.8°C at 760 mmHg
MDL番号:MFCD04114127
保管方法:Keep in a tight container and store at 2°C~8°C

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Darovasertib
The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Darovasertib, a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma”. Uveal melanoma (UM) is the most common primary intraocular malignancy. About half of primary uveal melanoma tumors metastasize but with no standard treatment. Most patients with metastatic uveal melanoma have been found to have mutations in GNAQ or GNA11, that are associated with consistent activation of the protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways.
IDEAYA's Darovasertib (IDE196) is a potent, selective small molecule inhibitor of PKC which stops activating PKC/MEK pathway. Darovasertib is under Phase 2 expansion and Phase 3 registrational trial with Crizotinib in GNAQ/11 metastatic cutaneous melanoma.